Trials / Recruiting
RecruitingNCT07223593
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
A Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled Trial
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,205 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Orforglipron | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2025-10-31
- Primary completion
- 2028-06-01
- Completion
- 2028-06-01
- First posted
- 2025-11-03
- Last updated
- 2026-04-17
Locations
138 sites across 16 countries: United States, Argentina, Australia, Brazil, Canada, China, France, India, Japan, Netherlands, Poland, Puerto Rico, Slovakia, South Korea, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07223593. Inclusion in this directory is not an endorsement.